Lyndra
Lyndra is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Lyndra.
Lyndra is a company.
Key people at Lyndra.
Key people at Lyndra.
Lyndra Therapeutics is a clinical-stage biopharmaceutical company developing oral, ultra-long-acting sustained release therapies delivered via a single, normal-sized capsule that provides consistent drug levels for up to a week or a month.[1][3][8] It targets diseases where non-adherence to daily dosing drives poor outcomes, such as schizophrenia, diabetes, cardiovascular disease, and opioid use disorder, with a pipeline including risperidone (Phase 3 for schizoaffective disorder), buprenorphine (Early Phase 1 for opioid-related disorders), and others like LYN-163 for malaria.[1][2] The company serves patients, caregivers, and healthcare systems burdened by frequent dosing, solving medication non-adherence—a key factor in treatment failure—through its proprietary Extended-Release Oral Capsule platform, backed by partners like the Bill & Melinda Gates Foundation and NIH.[1]
Lyndra's growth momentum includes advancing multiple clinical trials (e.g., starts in 2022–2025), a focus on established drugs with known safety profiles, and strategic collaborations for commercialization.[2][3]
Founded in 2015 and headquartered in Watertown, MA, Lyndra emerged from breakthroughs in drug delivery technology.[2] Key founders include Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr., a renowned MIT professor in chemical engineering and drug delivery whose expertise in controlled-release systems laid the groundwork.[2] The idea stemmed from addressing pill burden and non-adherence, evolving from academic innovation at institutions like MIT and Northeastern (where co-ops contributed early) into a platform for weekly or monthly oral dosing.[1][2][5] Pivotal early traction came from partnerships with global health organizations, enabling pipeline expansion beyond CNS disorders to public health challenges like malaria.[1][2]
Lyndra rides the wave of precision drug delivery and patient-centric therapeutics, capitalizing on rising demand for adherence solutions amid chronic disease epidemics and post-pandemic healthcare shifts.[1][3] Timing aligns with advances in biomaterials and formulation tech from academia (e.g., MIT), enabling oral alternatives to injections amid a biotech boom in long-acting formulations.[2][5] Market forces like aging populations, mental health crises, and opioid epidemics favor it, as non-adherence costs billions annually; Lyndra influences the ecosystem by partnering with philanthropies for underserved areas (e.g., malaria), potentially disrupting daily oral meds and inspiring platform licensing.[1][2][4]
Lyndra is poised for milestones like Phase 3 readouts for risperidone and buprenorphine advancement, with potential approvals unlocking commercialization via partners.[2][3] Trends in AI-optimized formulations, global health funding, and value-based care will accelerate its platform across new entities, expanding influence from CNS/opioids to infectious diseases.[1][2] As trials progress (e.g., 2025 starts), expect partnerships or acquisitions by big pharma seeking oral long-acting edges, solidifying its role in reinventing medicine from daily burden to simplified, effective dosing.[3][4]
